[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

August 2018 - April 2015

Decade

Year

Issue

April 2016, Vol 2, No. 4, Pages 413-549

Original Investigation

Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer

Abstract Full Text
free access
JAMA Oncol. 2016;2(4):445-452. doi:10.1001/jamaoncol.2015.4720

This prospective, single-arm study examines the results of a 10-item questionnaire administered to women with breast cancer to gain patient perspective on self-reported chemotherapy-related adverse effects after the first and third cycles of chemotherapy.

Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2016;2(4):453-461. doi:10.1001/jamaoncol.2015.4655

This secondary analysis of clinical trial data examines older men assigned to intermittent androgen-deprivation therapy to determine frequency of bone, endocrine, cognitive, ischemic, and thrombotic events.

Cancer Mortality Among Recipients of Solid-Organ Transplantation in Ontario, Canada

Abstract Full Text
free access
JAMA Oncol. 2016;2(4):463-469. doi:10.1001/jamaoncol.2015.5137

This population-based cohort study used national transplant registry data to assess whether solid-organ transplant recipients are at increased risk of cancer mortality compared with the general population.

Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer

Abstract Full Text
free access
JAMA Oncol. 2016;2(4):471-480. doi:10.1001/jamaoncol.2015.4955

This cohort study of 1090 men tests 9 DNA damage and repair pathways using 17 gene sets from prostatectomy samples to identify better biomarkers for patients at the highest risk to guide therapy intensification.

Inherited Mutations in Women With Ovarian Carcinoma

Abstract Full Text
free access
JAMA Oncol. 2016;2(4):482-490. doi:10.1001/jamaoncol.2015.5495

This cohort study of 1915 women with ovarian carcinoma assesses the frequency and importance of germline mutations in cancer-associated genes in ovarian cancer.

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or BothThe TRAPEZE Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2016;2(4):493-499. doi:10.1001/jamaoncol.2015.5570

The TRAPEZE study compares the clinical effectiveness and cost-effectiveness of docetaxel alone or with strontium-89, zoledronic acid, or both in patients with bony metastatic castrate-refractory prostate cancer.

Comparison of Gonadotropin-Releasing Hormone Agonists and OrchiectomyEffects of Androgen-Deprivation Therapy

Abstract Full Text
free access
JAMA Oncol. 2016;2(4):500-507. doi:10.1001/jamaoncol.2015.4917

This population-based cohort study examines the comparative effectiveness of gonadotropin-releasing hormone agonists (GnRHa) vs bilateral orchiectomy in men with metastatic prostate cancer to determine whether GnRHa is associated with higher risks of several clinically relevant adverse effects.

Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy

Abstract Full Text
free access
JAMA Oncol. 2016;2(4):508-516. doi:10.1001/jamaoncol.2015.4935

This study investigates the long-term effect of axillary pathologic complete response on relapse-free and overall survival among women with breast cancer with cytologically confirmed axillary lymph node metastases treated with primary systemic chemotherapy.

Brief Report

Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva

Abstract Full Text
free access
JAMA Oncol. 2016;2(4):518-522. doi:10.1001/jamaoncol.2015.6326

This cohort study of 71 women with squamous cell carcinoma (SCC) of the cervix and vulva determines that recurrent copy gains of genes encoding the PD-1 (programmed cell death protein 1) ligands provide a genetic basis for PD-L1 (programmed cell death 1 ligand 1) expression in a subset of SCCs.

Research Letter

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib

Abstract Full Text
free access
JAMA Oncol. 2016;2(4):541-543. doi:10.1001/jamaoncol.2015.5009

This retrospective analysis suggests that osimertinib may be more potent than rociletinib at clinical doses in patients exposed to more than 1 third-generation EGFR tyrosine kinase inhibitor.

Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United StatesA Nationwide Survey Analysis

Abstract Full Text
free access
JAMA Oncol. 2016;2(4):543-545. doi:10.1001/jamaoncol.2015.5871

This survey study assesses the prevalence of nonrecommended screening for prostate cancer and breast cancer in the United States.

Review

Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers

Abstract Full Text
has active quiz
JAMA Oncol. 2016;2(4):529-534. doi:10.1001/jamaoncol.2015.5927

This narrative review summarizes toxic effects of sorafenib in patients diagnosed with thyroid and other cancers.

JAMA Oncology Clinical Challenge

Shoulder Pain After Definitive Lung Radiotherapy

Abstract Full Text
JAMA Oncol. 2016;2(4):537-538. doi:10.1001/jamaoncol.2015.6591

A man in his 70s with rheumatoid arthritis and a 50-pack-year smoking history presented with a worsening unproductive cough, and workup identified a T2aN0M0 right upper lobe non–small-cell lung cancer; after treatment, he experienced abrupt onset of severe right shoulder pain. What is your diagnosis?

Viewpoint

Targeting the Cancer Moonshot

Abstract Full Text
JAMA Oncol. 2016;2(4):421-422. doi:10.1001/jamaoncol.2016.0328

This Viewpoint evaluates prevention as a component of cancer research.

Adjuvant Bone-Targeted Therapies for Postmenopausal Breast Cancer

Abstract Full Text
JAMA Oncol. 2016;2(4):423-424. doi:10.1001/jamaoncol.2015.5768

This Viewpoint explores recommendations for the inclusion of bisphosphonates in adjuvant therapy for postmenopausal breast cancer.

Addressing Skyrocketing Cancer Drug Prices Comes With TradeoffsPick Your Poison

Abstract Full Text
JAMA Oncol. 2016;2(4):425-426. doi:10.1001/jamaoncol.2015.5813

This Viewpoint asserts that the current model for cancer drug pricing in the United States is not sustainable, harms patients and families and the health care system, and calls for solutions that better balance access, affordability, and incentives to innovate.

Effects of Narrow Networks on Access to High-Quality Cancer Care

Abstract Full Text
JAMA Oncol. 2016;2(4):427-428. doi:10.1001/jamaoncol.2015.6125

This Viewpoint asks whether insurers are beginning to exclude stand-alone cancer centers in the form of “narrow networks” as a way to dissuade patients requiring expensive cancer care from choosing a particular health plan.

The Ethical Imperative of Healthy Paternalism in Advance Directive Discussions at the End of Life

Abstract Full Text
JAMA Oncol. 2016;2(4):429-430. doi:10.1001/jamaoncol.2015.6349

This Viewpoint discusses the components of successful end-of-life communication between patients and physicians.

From The JAMA Network

Mediterranean Diet and Its Association With Reduced Invasive Breast Cancer Risk

Abstract Full Text
JAMA Oncol. 2016;2(4):535-536. doi:10.1001/jamaoncol.2015.5679

This commentary discusses the results of the PREDIMED study, which asseed the effects of consumption of extra-virgin olive oil and the Mediterranean diet on reducing breast cancer risk.

Editorial

Missing Patients’ Symptoms in Cancer Care Delivery—The Importance of Patient-Reported Outcomes

Abstract Full Text
JAMA Oncol. 2016;2(4):433-434. doi:10.1001/jamaoncol.2015.4719

Thank You JAMA Oncology Authors, Peer Reviewers, and Readers

Abstract Full Text
JAMA Oncol. 2016;2(4):435-436. doi:10.1001/jamaoncol.2015.4391

Chemical or Surgical Castration—Is This Still an Important Question?

Abstract Full Text
JAMA Oncol. 2016;2(4):437-438. doi:10.1001/jamaoncol.2015.4918
Invited Commentary

Harms of Intermittent vs Continuous Androgen-Deprivation Therapy for Prostate Cancer

Abstract Full Text
JAMA Oncol. 2016;2(4):461-462. doi:10.1001/jamaoncol.2015.4682

Targeted Cancer Screening After Solid-Organ Transplantation

Abstract Full Text
JAMA Oncol. 2016;2(4):470. doi:10.1001/jamaoncol.2015.5172

DNA Damage and Repair Pathway Profiles as Biomarkers in High-Risk Prostate Cancer

Abstract Full Text
JAMA Oncol. 2016;2(4):480-481. doi:10.1001/jamaoncol.2015.4952

Germline Sequence Variants and Ovarian CancerKnown-Knowns and Known-Unknowns

Abstract Full Text
JAMA Oncol. 2016;2(4):491-492. doi:10.1001/jamaoncol.2015.5622

Parsing Pathologic Complete Response in Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer

Abstract Full Text
JAMA Oncol. 2016;2(4):516-517. doi:10.1001/jamaoncol.2015.4919
Cancer Care Chronicles

Practicing Hope

Abstract Full Text
JAMA Oncol. 2016;2(4):431-432. doi:10.1001/jamaoncol.2015.6413
Comment & Response

Pregnancy Rate and Preservation of Cyclic Ovarian Function With Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy

Abstract Full Text
JAMA Oncol. 2016;2(4):545-546. doi:10.1001/jamaoncol.2015.5740

Pregnancy Rate and Preservation of Cyclic Ovarian Function With Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy—Reply

Abstract Full Text
JAMA Oncol. 2016;2(4):546-547. doi:10.1001/jamaoncol.2015.5743

Role of Endoscopic vs Percutaneous Biliary Drainage in the Treatment of Malignant Biliary Tract Obstruction

Abstract Full Text
JAMA Oncol. 2016;2(4):547-548. doi:10.1001/jamaoncol.2015.6106

Role of Endoscopic vs Percutaneous Biliary Drainage in the Treatment of Malignant Biliary Tract Obstruction—Reply

Abstract Full Text
JAMA Oncol. 2016;2(4):548. doi:10.1001/jamaoncol.2015.6122

Relationship of Industry Sponsorship to Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment

Abstract Full Text
JAMA Oncol. 2016;2(4):548-549. doi:10.1001/jamaoncol.2016.0139

Relationship of Industry Sponsorship to Results of Cost-Effectiveness Analyses of Drugs Used in Breast Cancer Treatment—Reply

Abstract Full Text
JAMA Oncol. 2016;2(4):549. doi:10.1001/jamaoncol.2016.0142
Correction

Incorrect Sentence in the Abstract

Abstract Full Text
free access
JAMA Oncol. 2016;2(4):549. doi:10.1001/jamaoncol.2016.0571
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2016;2(4):415. doi:10.1001/jamaoncol.2015.3499
Peer Reviewers List

JAMA Oncology Peer Reviewers in 2015

Abstract Full Text
free access online only
JAMA Oncol. 2016;2(4):e160136. doi:10.1001/jamaoncol.2016.0136
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2016;2(4):413. doi:10.1001/jamaoncol.2015.3498
×